Wachowiak J, Labopin M, Miano M, Chybicka A, Stary J, Sterba J, Masszi T, Labar B, Maschan A, Kowalczyk J R, Lange A, Holowiecki J, Kalman N, Afanassiev B V, Dini G
Department of Paediatric Oncology, Hematology and Transplantology, University of Medical Sciences, Poznan, Poland.
Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S112-7. doi: 10.1038/bmt.2008.68.
The paediatric population of 19 eastern European countries amounts to approximately 80 million children. Between 1985 and 2004, the number of centres performing haematopoietic stem cell transplantation (HSCT) in children increased from 1 in 1985 to 24 in 2004 and the yearly number of paediatric HSCTs rose from 1 in 1985 to 291 in 2004. Altogether, 2342 transplants were reported to the EBMT Registry during this time (Poland 953, Czech Republic 501, Hungary 269, Russia 217, Croatia 129, Slovakia 71, Bulgaria 45, Serbia and Montenegro 36, Slovenia 35, Belarus 33, Estonia 26, Lithuania 19 and Romania 8). Out of the 2342 transplants, 1487 (63.5%) transplants were performed in paediatric centres, 453 (19.3%) in centres for adults and 402 (17.2%) in combined centres. The number of children who underwent autologous HSCT (auto-HSCT) was 1053 (45%), whereas 1289 (55%) underwent allogeneic HSCT (allo-HSCT). Peripheral blood (PB) was the source of HSC in 751 (71.3%) out of 1053 auto-transplants, BM in 246 (23.4%) and PB+BM in 52 (4.9%) (missing data in 4, that is, 0.4%). Among the 1289 allo-transplants, BM was the source of HSC in 827 (64.3%), PB in 416 (32.3%), CB in 23 (1.8%) and BM+PB in 14 (1.1%) (missing data in 9, that is, 0.7%). Among them, 728 (57.4%) obtained HSC from MSD, 322 (25.4%) from UD, 195 (15.4%) from MMFD, 14 (1.1%) from CB family donor and 9 (0.7%) from CB unrelated donor (missing data in 21, that is, 1.6%). The number of children who underwent allo-HSCT for malignant diseases was 945 (73.4%), including ALL 376 (29.2%), AML 234 (18.2%), CML 177 (13.8%), MDS 97 (7.5%), NHL 35 (2.7%) and other malignancy 31 (2.4%), while 339 (26.9%) for non-malignant disorders, including SAA 202 (15.7%), immunodeficiencies 61 (4.7%), inborn errors of metabolism 40 (3.1%), Fanconi anaemia 19 (1.5%) and others 17 (1.3%). Out of 1053 recipients of auto-HSCT, 168 (16%) were transplanted for neuroblastoma, 129 (12.2%) for NHL, 124 (11.7%) for AML, 114 (10.8%) for ALL, 109 (10.4%) for Hodgkin's disease, 62 (5.9%) for Ewing's sarcoma, 16 (1.5%) for CNS tumour, 15 (1.4%) for Wilms tumour and 316 (30%) for other tumours. In 2001, the EBMT in collaboration with the European School of Haematology (ESH) developed the Outreach Programme, that is a programme supporting emerging HSCT projects and transplant centres in countries with limited resources and/or experience.
19个东欧国家的儿童人口约为8000万。1985年至2004年间，进行儿童造血干细胞移植（HSCT）的中心数量从1985年的1个增加到2004年的24个，儿童HSCT的年数量从1985年的1例增加到2004年的291例。在此期间，共有2342例移植报告给欧洲血液与骨髓移植登记处（EBMT登记处）（波兰953例、捷克共和国501例、匈牙利269例、俄罗斯217例、克罗地亚129例、斯洛伐克71例、保加利亚45例、塞尔维亚和黑山36例、斯洛文尼亚35例、白俄罗斯33例、爱沙尼亚26例、立陶宛19例和罗马尼亚8例）。在这2342例移植中，1487例（63.5%）在儿科中心进行，453例（19.3%）在成人中心进行，402例（17.2%）在综合中心进行。接受自体HSCT（auto-HSCT）的儿童数量为1053例（45%），而接受异基因HSCT（allo-HSCT）的儿童数量为1289例（55%）。在1053例自体移植中，751例（71.3%）的造血干细胞来源为外周血（PB），246例（23.4%）为骨髓（BM），52例（4.9%）为PB + BM（4例数据缺失，即0.4%）。在1289例异基因移植中，827例（64.3%）的造血干细胞来源为BM，416例（32.3%）为PB，23例（1.8%）为脐血（CB），14例（1.1%）为BM + PB（9例数据缺失，即0.7%）。其中，728例（57.4%）的造血干细胞来自同胞全相合供者（MSD），322例（25.4%）来自单倍体相合供者（UD），195例（15.
